

PTO/SB/82 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/499,468
Filing Date	February 7, 2000
First Named Inventor	Ralph Alderson
Art Unit	1647
Examiner Name	Landsman, Robert S.
Attorney Docket Number	1488.100000F/EKS/HCC

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners associated with the Customer Number: **28730**

Please change the correspondence address for the above-identified application to:

The address associated with
Customer Number:

28730

OR

<input type="checkbox"/> Firm or Individual Name			
---	--	--	--

Address			
---------	--	--	--

City		State	Zip
------	--	-------	-----

Country			
---------	--	--	--

Telephone		Email
-----------	--	-------

I am the:

- Applicant/Inventor.
 Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
-----------	--	--	--

Name	James H. Davis, Ph.D.		
------	-----------------------	--	--

Date	2/10/06	Telephone	(301) 251-6039
------	---------	-----------	----------------

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 1 forms are submitted.


This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

491492

DUPLICATE
as filed March 14, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



MAR 03 2006 re Patent Application of:
Alperson et al.

Docket No.: PF112U1

Application No.: 09/499,468-Conf. #1320

Allowed: December 30, 2004

Filed: February 7, 2000

Group Art Unit: 1647

For: Use of Vascular Endothelial Growth Factor to
Treat Photoreceptor Cells (as amended)

Examiner: R.S. Landsman

**STATEMENT UNDER 37 C.F.R. § 3.73, REVOCATION OF PRIOR
POWERS OF ATTORNEY OR AUTHORIZATIONS OF AGENT, AND
POWER OF ATTORNEY OR AUTHORIZATION OF AGENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is the assignee of record of the entire right, title and interest for the above-identified application by virtue of an assignment from the inventors, recorded in the U.S. Patent and Trademark Office on July 25, 2000, at Reel 010954, Frame 0835. This assignment is directed to the present application, and all continuation and divisional applications thereof.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS. The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of the undersigned's knowledge and belief, HGS has title in the application as described above.

Revocation of Prior Powers of Attorney or Authorizations of Agent

HGS hereby revokes all previous powers of attorney or authorizations of agent given in the above-captioned application.

DUPLICATE
as filed March 14, 2005

Power of Attorney or Authorization of Agent

HGS hereby appoints the Practitioners at Customer Number 22195 as its attorneys or agents with full power of substitution, association, and revocation to prosecute the above-captioned application, including any continuations or divisionals thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith:

On behalf of Human Genome Sciences, Inc.:

For: Human Genome Sciences, Inc.

Signature: James H. Davis

Name: James H. Davis, Ph.D.

Title: Executive Vice President and General Counsel

Date: March 11, 2005

BEST AVAILABLE COPY

**DO NOT FORWARD TO ASSIGNMENT
BRANCH NOT FOR RECORDATION**

ASSIGNMENT

**DO NOT FORWARD TO ASSIGNMENT
BRANCH NOT FOR RECORDATION**

For good and valuable consideration, the receipt of which is hereby acknowledged, each of the undersigned, Ralph ALDERSON, Robert MELDER, Viktor ROSCHKE, Steven M. RUBEN and Craig A. ROSEN, hereby sell(s), assign(s) and transfer(s) to **Human Genome Sciences, Inc.** ("Assignee") having a place of business at 9410 Key West Avenue, Rockville, MD 20850, its successors, assigns and legal representatives, his/her entire right, title and interest for the United States and all other countries, in and to the improvements(s) known as:

VASCULAR ENDOTHELIAL GROWTH FACTOR-2

for which application for United States Letters Patent was filed on February 7, 2000, and assigned U.S. Application Serial No. 09/499,468, and in and to said application and all divisional, continuing, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States and all other countries on any of said improvements, and in and to all original and reissued patents which have been or shall be issued in the United States and all other countries on said improvements (hereinafter collectively, the "Patent Rights").

The undersigned further agrees that said Assignee may apply for and receive Letters Patent for said improvements in its own name; and, when requested, without charge to but at the expense of Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue and all other patent applications on all such improvements; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives all facts known to the undersigned relating to said improvements and the history thereof; and do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements and all applications for patent and all patents on said improvements in Assignee, its successors, assigns and representatives.

The undersigned hereby represents and warrants to Assignee, its successors, assigns and representatives that no assignment, grant, mortgage, license or other right or agreement affecting the rights and property herein conveyed has been made to others by the undersigned and that full right to convey the same as expressed herein is possessed by the undersigned.


The undersigned hereby grants the power to: James H. Davis (Reg. No. 40,582), Kenley K. Hoover (Reg. No. 40,302), Michele M. Wales (Reg. No. 43,975), Jonathan L. Klein (Reg. No. 41,119), and Joseph J. Kenny (Reg. No. 43,710) of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, Maryland, 20850 to insert on this Assignment any further


BEST AVAILABLE COPY


DO NOT FORWARD TO ASSIGNMENT
BRANCH NOT FOR RECORDATION


identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


IN WITNESS WHEREOF, this Assignment is executed by the undersigned on the date(s) opposite their signature(s):

Inventor's Signature:  Date: 5/10/00
Ralph Alderson

Inventor's Signature:  Date: 5/11/00
Robert Melder

Inventor's Signature:  Date: 5/12/00
Viktor Roschke

Inventor's Signature:  Date: 5/9/00
Steven M. Ruben

Inventor's Signature:  Date: 5/12/00
Craig A. Rosen

DO NOT FORWARD TO ASSIGNMENT
BRANCH NOT FOR RECORDATION